A Phase 1/2 Trial for Patients with Newly Diagnosed Anal Cancer Treated with Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001
Categories (click each to see list of all clinical trials associated with that category): GI (ONC)
Current Status: Open
Phase: I/II (Cancer Control)
Principal Investigator: Lin, Chi
Contact Information:
Amy Filler-Katz, RN, BSN, CCRP
402-552-2790
afillerkatz@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT03386500?term=NCT03386500&rank=1
Summary
In this Phase 1/2 study, the investigators will conduct a dose-escalation study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. The primary objective is to determine the maximum tolerated dose (MTD) of BMX-001 in ASCC patients receiving RT and concurrent 5FU/mitomycin chemotherapy.